1. Medicines
  2. Ophthalmology
  3. LUCENTIS® (ranibizumab)

Prescribing information

 

LUCENTIS® (ranibizumab)

   

LUCENTIS offers patients efficacy across multiple indications1

 

Six different coloured circles with the following indications: DMO, wAMD, PDR, RVO, CNV, ROP.
Six different coloured circles with the following indications: DMO, wAMD, PDR, RVO, CNV, ROP.
Six different coloured circles with the following indications: DMO, wAMD, PDR, RVO, CNV, ROP.
Six different coloured circles with the following indications: DMO, wAMD, PDR, RVO, CNV, ROP.
Six different coloured circles with the following indications: DMO, wAMD, PDR, RVO, CNV, ROP.
Six different coloured circles with the following indications: DMO, wAMD, PDR, RVO, CNV, ROP.
 

LUCENTIS CELEBRATES 10-YEAR ANNIVERSARY IN DMO†

Click the button below to see the key efficacy data for LUCENTIS in the treatment of visual impairment due to DMO.

 

 

Resources to help you with your LUCENTIS patients

 

Preview of Education booklet in DMO for Resources for HCPs.

Resources for HCPs

Access the resources for HCPs >

Preview of Understanding DMO booklet for Resources for HCPs to share with patients.

Resources for HCPs to share with patients

Access the patient resources >

 

We cover a variety of topics about a-VEGF patients, treatment and service impact due to COVID-19 in a variety of webinars and podcasts. 

 

Large icon signifying a webinar to accompany the link to Webinar Highlights page.

Webinar highlights 

Access the webinar highlights >

Large icon signifying a microphone and sound waves to accompay the link to the Ophthalmology podcasts page.

Ophthalmology podcasts

Access the ophthalmology podcasts >

 

 

*LUCENTIS 0.2 mg is indicated in preterm infants for:1
The treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.

†LUCENTIS 0.5 mg is indicated in adults for:1
The treatment of neovascular (wet) age-related macular degeneration (AMD)
The treatment of visual impairment due to diabetic macular oedema (DMO)
The treatment of proliferative diabetic retinopathy (PDR)The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
The treatment of visual impairment due to choroidal neovascularisation (CNV).
‡Once maximum VA is achieved and/or disease activity is stable.

DMO, diabetic macular oedema; CNV, choroidal neovascularisation; HCP, healthcare professional; PDR, proliferative diabetic retinopathy; proliferative diabetic retinopathy; ROP, retinopathy of prematurity; RVO, retinal vein occlusion; T&E, treat & extend;‡ VEGF, vascular endothelial growth factor; wAMD, wet age-related macular degeneration.

 

Reference

  1. Lucentis (ranibizumab) Summary of Product Characteristics, July 2020.
  2. Lucentis® SmPC history.    
  3. Dorairaj E, et al. Ranibizumab in diabetic macular oedema: 2 year audit data. Presented at ESCRS 2017, Maastricht, The Netherlands.     
  4. Prakash, P, et al. To determine the efficacy of treatment of Ranibizumab over a period of 5 years in patients with DMO at PAH, Harlow, presented at Royal College of Ophthalmology congress 2021.    
  5. Mitchell P, et al. Effectiveness and safety of ranibizumab 0.5 mg in treatment-naïve patients with diabetic macular edema: Results from the real-world global LUMINOUS study. PLoS One. 2020;15(6):32492069.
 
Rate this content: 
No votes yet
UK | September 2021 | 147223
Oncology
Product
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]